Single-nucleotide polymorphism of rs7944135 (macrophage-expressed gene 1) is associated with hepatitis B surface antigen seroclearance in chronic hepatitis B infection: A cohort study

Lalu Muhammad Irham, MSa,b,c, Henry Sung-Ching Wong, PhDa,b, Dyah Aryani Perwitasari, PhDc, Wan-Hsuan Chou, MSa,b, Hwai-I Yang, PhDd,e,f, Wei-Chiao Chang, PhDb,d,f,g,*

Abstract
Clearance of the hepatitis B surface antigen (HBsAg) is the ultimate aim of treatment for patients with chronic hepatitis B (CHB) infection. Genetic, factor age, and gender were reported to be involved in the clearance of HBsAg. However, the rate of HBsAg seroclearance in CHB patients is still low globally and few of the single-nucleotide polymorphism (SNP) had been identified to be associated with HBsAg seroclearance in CHB patients.

Recently, 3 associated SNPs (rs7944135, rs171941, and rs6462008) were reported in the clearance of HBsAg in the Korean population. However, these SNPs have not been investigated in the CHB Taiwanese population. In present study, these 3 SNPs were genotyped in 2685 Taiwanese CHB patients including 493 CHB patients with HBsAg seroclearance and 2072 without HBsAg seroclearance.

We observed that SNP rs7944135 was solely associated with HBsAg seroclearance. Subjects with the AA genotype at rs7944135 of macrophage-expressed gene 1 had a higher susceptibility to HBsAg clearance, compared to those with the AG or GG genotype under the genotypic model (odds ratio [OR] = 1.74, 95% confidence interval [CI] = 1.13–2.66, P = .014). According to the cumulative fraction curve with the log-rank test revealed that patients with the AA genotype of rs7944135 showed higher susceptibility to occur HBsAg seroclearance (P = .039) and HBV DNA undetectable (P = .0074) compared to those with the AG or GG genotype.

This study examined the associations of 3 SNPs (rs7944135, rs171941, and rs6462008) with HBsAg seroclearance, and we identified that rs7944135 is solely associated with HBsAg seroclearance in Taiwanese CHB patients.

Abbreviations: CHB = chronic hepatitis B, CI = confidence interval, GWASs = genome-wide association studies, HBsAg = hepatitis B surface antigen, HBV = hepatitis B virus, MPEG1 = macrophage-expressed gene 1, OR = odds ratio, SNPs = single-nucleotide polymorphisms.

Keywords: CHB, HBsAg seroclearance, HBV, rs7944135, single-nucleotide polymorphism

1. Introduction
The hepatitis B virus (HBV) was discovered over 5 decades ago. Although a prophylactic vaccine has been available, HBV infection is still a serious problem globally. World Health Organization (2018) estimated that there were 257 million new cases and 887,000 deaths from HBV. Most of the deaths were caused by...
complications, including cirrhosis and hepatocellular carcinoma (HCC),[1,2] Eventually, the goal of therapy in CHB patients is to alleviate and prevent this complication.

Chronic hepatitis B (CHB) infection can be confirmed by its complicated serological pattern, while hepatitis B surface antigen (HBsAg) was reported to be well-established as a serum marker in the natural history of HBV infection. A low level of the HBsAg is associated with sustained immune control, seroclearance of HBsAg, and a lower risk of HCC.[3] A meta-analysis study further confirmed the role of the HBsAg as a predictive marker of hepatitis B, liver cirrhosis, and HCC development, and the rate of spontaneous HBsAg seroclearance,[4] an important milestone in the natural history of CHB infection. In addition, the serological profiles of chronic HBV infection also revealed that plasma HBV DNA levels can serve as a marker of disease progress.[5] In general, CHB is defined as the presence of the HBsAg for more than 6 months after an HBV infection[6] and spontaneous HBsAg seroclearance is defined as the loss of the HBsAg at least 6 months apart on 2 occasions and continuing to remain to absent up to the last visit.[7] However, the rate of HBsAg seroclearance in CHB patients is varied globally at an estimated 1% to 2% annually,[8] at approximately, 0.41% to 1.58% in Europe,[9,10] 0.56 to 0.65% in north and south America, respectively[11,12] and 0.12% to 2.38% Asian,[13] 0.4% per year reported in Korea,[14] 2.5% in the Goto Islands of Japan,[15] and 1.15% per year was reported in Taiwan.[13]

The clearance of the HBsAg in HBV infection is influenced by many factors, such as genetic and host factors including age, sex, and race. Several studies identified that host genetic polymorphisms may be associated with clinical outcomes of HBV, including HLA DQ (HLA-DQ) and DP (HLA- DP),[16,17] IL28B,[18] HLA-DPB1,[19] tumor necrosis factor-α (TNF-α),[20] and monocyte chemotactic protein-1 (MCP-1).[21] Some CHB-associated loci, such as HLA-DPB1, HLA-DQA2, and HLA-DQB, also reported by previous genome-wide association studies (GWASs), were identified in a Taiwanese population.[22] However, more the genetic studies still need to be examined in HBV infection, considering of HBsAg seroclearance as a marker of cure of HBV infection. Recently, Kim et al indicated that three new SNPs (rs7944135, rs171941, and rs6462008) were associated with HBsAg seroclearance in a Korean population. Thus, the purpose of this study was to investigate whether the polymorphisms reported by the Korean group are associated with clearance of the HBsAg in Taiwanese HBV patients.

2. Materials and methods

2.1. Study subjects

In total, 2565 CHB patients (including 493 with HBsAg seroclearance and 2072 without HBsAg seroclearance) satisfied the inclusion criteria for follow-up of CHB, which were recruited during 1991 to 1992 from 7 area in Taiwan (Sanchi, Chutung, Pozou, Kaoshu, Makung, Hushi, and Paisha). All of the study participants were ethnic Chinese (ie, Taiwanese). All participants in this study provided written informed consent before participation. This project was approved by the ethics committees at Academia Sinica, Taiwan.

2.2. Clinical evaluation and SNP selection

All patients were tested for hepatitis B or virological markers in the liver, including HBsAg was measured using radioimmunoassay with commercial kits (Abbott Laboratories, North Chicago), HBV DNA were measured by polymerase chain reaction (PCR) using the Cobas Amplicor HBV monitor test kit (Roche Diagnostics, Indianapolis, IN) and alanine transaminase (ALT) ALT using chemistry autoanalyzer (Model 736; Hitachi, Tokyo, Japan) using commercial reagents (Biomérieux, Marcy L’Étoile, France). HBsAg seroclearance were defined as loss of HBsAg in serum at least 6 months apart on 2 occasions and continued to absent up to the last visit. While without HBsAg seroclearance were defined as positive of HBsAg in serum for more than 6 months apart and continuously detected up to the last visit.

The SNPs we investigated in this present study were the replicated study from a GWAS applied in a Korean CHB population reported by Kim et al. Kim et al reported 3 SNPs (rs7944135, rs171941, rs6462008) associated with seroclearance of the HBsAg in Korean CHB patients. These 3 SNPs were confirmed to exist in a Taiwanese CHB population.

2.3. DNA extraction and genotyping of the 3 SNPs

DNA was extracted from blood samples and subsequently centrifuged at 3000 rpm for 10 minutes at 4°C to separate cells and plasma. Specimens were stored below -70°C. The buffy coat was isolated from blood samples, and red blood cells (RBCs) were lysed after the addition of RBC lysis buffer.

Three SNPs (rs7944135, rs171941, and rs6462008) were assessed by genotyping. Genotyping assays were performed using a TaqMan allelic discrimination assay (Applied Biosystems, Foster City, CA). PCRs were subsequently performed in a 96-well microtiter plate with either an ABI7500 real-time PCR or ABI9700 Thermal Cycler under the following conditions: 10 minutes of denaturing at 95°C, followed by 45 cycles of 15 seconds of denaturing at 95°C and 30 seconds for annealing at 60°C, with 1 minutes of a final extension at 60°C. Fluorescence signals from amplicons were analyzed using System SDS software vers. 1.2.3 (Applied Biosystems).

2.4. SNP annotation data query

Associations between gene expression profiles and the SNPs were confirmed by examining the expression quantitative trait loci (e-QTL) through (genotype-tissue expression [GTEx]) Portal database (http://www.gtexportal.org/home/). The GTEx database shows expressions of genes in a variety of tissues.

2.5. Statistical analysis

We performed all analyses using the R environment (https://cran.r-project.org/ and https://www.r-project.org/). We used Student t test to compare the age, ALT, and follow-up duration between the CHB patients with HBsAg seroclearance and without HBsAg seroclearance groups. We used logistic regression analyses to obtain adjusted OR between the case with HBsAg seroclearance and gender, age, ALT, and follow-up duration. Associations between SNPs and HBsAg seroclearance under genotype and recessive models were assessed using the “SNPassoc” package. The association between (the rs7944135 genotype AA, AG, and GG) and (HBsAg seroclearance and undetectable of HBV DNA) were also modeled using time to event analysis utilized cumulative fraction curve using cumulative hazard function and log-rank test by “Survival and survminer” package. While, days between enrollment to undetectable of HBV DNA and occurring HBsAg seroclearance was used at the time scale.
Follow-up duration in the CHB patients with HBsAg seroclearance and without HBsAg seroclearance tended to more likely appeared in males than in females (OR = 1.76, 95% [1.13–2.66], P = .014). Furthermore, we found a 1.74-fold increased risk of acquiring HBsAg seroclearance associated with the AA genotype of rs7944135 under the recessive model (OR = 1.74, 95% [1.13–2.66], P = .014).

### Table 1
Baseline characteristics of the 2565 hepatitis B virus study participants.

| Characteristic              | With seroclearance (N = 493) | Without seroclearance (N = 2072) | P-value | Adjusted odds ratio (95%CI)† | P-value  |
|----------------------------|-------------------------------|-----------------------------------|---------|-----------------------------|----------|
| Male gender, n (%)         | 361 (73.2)                    | 1325 (63.9)                       | <.001†  | 1.51 (1.21–1.89)            | <.001†   |
| Mean (SD) age, yr          | 59 ± 9.74                     | 46.3 ± 9.53                       | <.001†  | 1.04 (1.03–1.05)            | <.001†   |
| Age range, yr              | 30–65                         | 30–65                             |         |                             |          |
| ALT, U/L                   | 17.7 ± 23.8                   | 16.5 ± 19.8                       | .24†    | 1.00 (0.99–1.00)            | .665     |
| Follow-up duration         |                               |                                   | <.001†  | 0.93 (0.91–0.95)            | <.001†   |
| Interval date, yr          | 6.29 ± 3.90                   | 7.79 ± 4.48                       |         |                             |          |
| Male                       | 66.6 ± 3.76                   | 9.17 ± 3.58                       |         |                             |          |
| Female                     | 5.21 ± 4.09                   | 5.40 ± 4.86                       |         |                             |          |

Data are presented as the number, mean ± SD, or median. ALT (normal range 5–40 U/L).

ALT = alanine aminotransferase, CI = confidence interval, SD = standard deviation.

† Significant at P < .05.

1 Adjusted for gender, age, and ALT.

### 3. Results

#### 3.1. Basic characteristics of chronic HBV-infected patients

We collected data on 2565 chronically HBV-infected subjects, including 493 CHB with HBsAg seroclearance (361 males and 132 females) and 2072 CHB without HBsAg seroclearance (1325 males and 747 females) in this study. The numbers of CHB male patients in the 2 groups included 361 with HBsAg seroclearance and 1325 without HBsAg seroclearance (P < .001). Average ages in the CHB patients with HBsAg seroclearance and without HBsAg seroclearance group were 50 and 46.3 years, respectively (P < .001), with an age range of 30 to 65 years. Mean of serum ALT values were 17.7 and 16.5 U/L, respectively (P = .24) (Table 1). The lengths of follow-up duration in the CHB patients with HBsAg seroclearance and without HBsAg seroclearance group were 6.29 years (6.66 years for male and 5.21 years for females) and 7.79 years (9.17 years for males and 5.40 years for females), respectively. Table 1 shows that subjects with HBsAg seroclearance were more likely to be older (odds ratio [OR] = 1.04, 95% [1.03–1.05]; P < .001). In addition, HBsAg seroclearance tended to more likely appeared in males than in females (OR = 1.51, 95% [1.21–1.89]; P < .001) even after adjusted for gender, age, and ALT. The follow-up duration was significantly shorter (P < .001) in the patients with HBsAg seroclearance than the group of patients without HBsAg seroclearance.

#### 3.2. Association of polymorphisms with HBsAg seroclearance

We investigated the association between genetic polymorphisms of 3 SNPs (rs7944135, rs171941, and rs6462008) and HBsAg seroclearance (Table 2). Genotype and recessive models were applied to assess associations of the HBsAg with the 3 SNPs. Our results revealed that the rs7944135 SNP was solely associated with HBsAg seroclearance. The rs7944135 SNP was found to be significantly associated with HBsAg seroclearance in the genotype and recessive model after adjusted with gender, age, and ALT, at P < .05. This result indicated that HBV carriers with the AA genotype of rs7944135 were more susceptible to HBsAg seroclearance compared to those with the AG or GG genotype of rs7944135. However, the 2 other SNPs (rs171941, and rs6462008) showed no correlation with HBsAg seroclearance (Table 2). A significant association between the rs7944135 AA genotype and HBsAg seroclearance was found 1.76-fold higher susceptibility to clearance of the HBsAg, compared to those with the AG or GG genotype (OR = 1.76, 95% [1.14–2.72], P = .045). Furthermore, we found a 1.74-fold increased risk of acquiring HBsAg seroclearance associated with the AA genotype of rs7944135 under the recessive model (OR = 1.74, 95% [1.13–2.66], P = .014).

### Table 2
Associations of MPEG1 with hepatitis B surface antigen seroclearance in 2565 hepatitis B virus patients.

| SNP      | Genotype | With seroclearance (%) (N = 493) | Without seroclearance (%) (N = 2072) | Genotype | OR (95% CI)† | P-value  | OR (95% CI)† | P-value  |
|----------|----------|----------------------------------|--------------------------------------|----------|--------------|----------|--------------|----------|
| rs7944135| AA       | 33 (6.7)                         | 77 (3.8)                             |          | 1.76 (1.14–2.72) | .045†    | 1.74 (1.13–2.66) | .014†    |
|          | AG       | 148 (30.0)                       | 600 (29.7)                           |          | 1.05 (0.84–1.31) | Reference|                 |          |
|          | GG       | 312 (63.3)                       | 1342 (66.5)                          |          | Reference     |          | Reference     |          |
| rs171941 | AA       | 35 (7.3)                         | 146 (7.2)                            |          | 0.86 (0.69–1.06) | .349     | 0.95 (0.65–1.41) | .811     |
|          | AG       | 170 (35.3)                       | 775 (38.4)                           |          | 0.90 (0.60–1.33) | Reference|                 |          |
|          | GG       | 277 (57.5)                       | 1094 (65.4)                          |          | Reference     |          | Reference     |          |
| rs6462008| TT       | 142 (29.5)                       | 540 (26.9)                           |          | 0.92 (0.69–1.23) | .519     | 1.01 (0.79–1.28) | .952     |
|          | GT       | 232 (48.1)                       | 1015 (50.5)                          |          | 0.87 (0.69–1.10) | Reference|                 |          |
|          | GG       | 108 (22.4)                       | 456 (22.7)                           |          | Reference     |          | Reference     |          |

CI = confidence interval, OR = odds ratio, SNP = single-nucleotide polymorphism.

† The significant P-value is in bold.

‡ Adjusted for gender, age, and ALT.
3.3. The minor allele frequency of 3 SNPs in different populations

The Table 3 shows the minor allele frequency (MAF) of 3 SNPs (rs7944135, rs171941, and rs6462008) in different populations (eg, Asian and European), which were these 2 population were reported higher susceptible to have HBsAg seroclearance in compare to another region worldwide.[23] MAFs of African, American, European, and Asian were extracted from the HaploReg browser v4.1 (https://pubs.broadinstitute.org/mammals/haploreg/haploreg.php); MAFs of the TWB were obtained from the Taiwan View website (https://taiwanview.twbiobank.org.tw/index). Table 3 showed that our result was close to those in reference to Asian including a Taiwan biobank (TWB) population.

3.4. Correlation between macrophage-expressed gene 1 rs7944135 and days of HBsAg seroclearance

In addition, we confirmed the correlation between the time taken to HBsAg seroclearance and the genotype of the macrophage-expressed gene 1 (MPEG1) gene SNP rs7944135. Log-rank test showed significant differences in the time taken to occur HBsAg seroclearance among the MPEG1 gene rs7944135 genotypes of AA, AG, and GG (P = .039). The cumulative fraction curve showed a trend of HBV carriers with the AA genotype of rs7944135 indicating higher susceptibility to HBsAg seroclearance compared to those with the AG or GG genotype (Fig. 1).

3.5. Correlation between the MPEG1 rs7944135 genotype and days of HBV DNA undetectable

We further investigated the correlation between the time taken to HBV DNA undetectable and MPEG1 gene rs7944135 genotypes: AA, AG, and GG. Log-rank test showed significant differences among MPEG1 gene SNP rs7944135 genotypes of AA, AG, and GG in the time taken to HBV DNA undetectable (P = .0074). The cumulative fraction curve showed that a trend of the AA genotype of rs7944135 of HBV carriers had a higher rate to undetected of HBV DNA versus the AG and GG genotypes (Fig. 2).

3.6. SNP annotation of e-QTLs of rs7944135

To elucidate the association between SNP rs7944135 and gene expression, we used the publicly available databases GTEx Portal (http://www.gtexportal.org/home/) to obtain the tissue e-QTLs. As shown in Table 4 and Figure 3 the AA genotype of rs7944135 had highly expressed of MPEG1 gene if compared to AG and GG genotype.

4. Discussion

Clearance of the HBsAg is an important indicator of recovery from CHB.[24] It was reported that HBsAg seroclearance is associated
with the prognosis of CHB.\textsuperscript{[25]} Clearance of the HBsAg in HBV is influenced by many factors, including genetic and host factors such as age, sex, and race.\textsuperscript{[26]} Our approach in this study was to confirm associations the factors of genetic, age, and gender with HBsAg seroclearance. In the present study, we replicated a GWAS study of associations the factors of genetic, age, and gender with HBsAg seroclearance in the Taiwanese CHB population.\textsuperscript{[13,27]} This study showed that rs7944135 in MPEG1 is significantly associated with HBsAg seroclearance in a Taiwanese CHB population. We observed that subjects with the AA genotype of MPEG1 rs7944135 had a higher susceptibility to HBsAg clearance, compared to those with the AG or GG genotype (OR = 1.76). In addition, we still found an association in rs7944135 with 1.74-fold increased risk of the AA genotype of HBsAg seroclearance occurring under the recessive model (OR = 1.74). Spontaneous HBsAg seroclearance can be predicted through serum levels of the HBsAg and HBV DNA.\textsuperscript{[24,32]} In terms of the time taken to the HBsAg seroclearance and undetected of HBV DNA, results showed that the rs7944135 AA genotype had a higher susceptibility to HBsAg seroclearance and HBV DNA undetectable compared to the AG and GG genotypes. A correlation between HBsAg and HBV DNA in serum was reported by Liu et al and revealed that the HBsAg level was not detected during the immune clearance phase as a result of declining HBV DNA levels. In addition, Coffin et al revealed that with a lower level of the HBsAg, there was a greater likelihood for loss of the HBsAg. The HBsAg at a low level was associated with a lower risk of prognosis of HCC.\textsuperscript{[31]} It is well known that the HBsAg contributes to the immunopathogenesis of persistent HBV infection, and a higher incidence of HBsAg seroclearance was associated with lower HBsAg levels.\textsuperscript{[33]}

MPEG1 is a specific gene that was identified in human and mice in macrophages and has many roles in immune responses.\textsuperscript{[34]} According to HaploReg V4.1, rs7944135 was located at 11q12.1 of MPEG1, and was involved in the changing chromatin status of primary T cells from peripheral blood, which plays a central role in the "primary immune response" of

\begin{table}
\centering
\caption{Cis-expression of quantitative trait loci results of the single-nucleotide polymorphism from genotype-tissue expression database.}
\begin{tabular}{|c|c|c|c|c|c|}
\hline
SNP ID & Genotype ID (Gencode) & Gene symbol & P-value & Effect size & Tissue & Actions \\
\hline
rs7944135 & 197629 & MPEG1 & .000072 & 0.11 & Muscle-skeletal & AA>AG>GG \\
110042 & DTX4 & 1.5e-16 & -0.33 & Muscle-skeletal & GG>AG>AA \\
110042 & DTX4 & .000015 & -0.15 & Heart-left ventricle & GG>AG>AA \\
110042 & DTX4 & 1.6e-7 & -0.22 & Lungs & GG>AG>AA \\
110042 & DTX4 & .000059 & -0.16 & Heart-atrial appendage & GG>AG>AA \\
110042 & DTX4 & 2.7e-12 & -0.31 & Esophagus-muscularis & GG>AG>AA \\
110042 & DTX4 & 4.7e-17 & -0.38 & Esophagus-mucosa & GG>AG>AA \\
110042 & DTX4 & 5.6e-11 & -0.29 & Cells-transformed fibroblasts & GG>AG>AA \\
110042 & DTX4 & 6.0e-9 & -0.31 & Adipose-subcutaneous & GG>AG>AA \\
110042 & DTX4 & 5.9e-9 & -0.32 & Adipose-subcutaneous & GG>AG>AA \\
110042 & DTX4 & .000032 & -0.14 & Adipose-subcutaneous & GG>AG>AA \\
\hline
\end{tabular}
\end{table}

SNP = single-nucleotide polymorphism.

\textsuperscript{\textcopyright}Irham et al. Medicine (2019) 98:51 www.md-journal.com

Figure 3. Cis-eQTLs of MPEG1 rs7944135 (Homo Alt (AA)>Het (AG)>Homo Ref (GG)) in muscle-skeletal. Cis-eQTLs = cis-expression quantitative trait loci, MPEG1 = macrophage-expressed gene 1.
cell-mediated immunity, the Information may suggest the role of MPEG1 in immune clearance of HBsAg in HBV infection. Furthermore, the MPEG1 gene has a role in immune response through encoding perforin-like protein and recognition of antigen.\textsuperscript{33} The perforin-like protein is predicted to be a perforin domain of membrane attack complex that helps cytotoxic T cells and natural killer cells kill virus infected cell.\textsuperscript{36,37} In our study, we demonstrated from The GTEx portal database that rs7944135 AA genotype shows the highest expressed of MPEG1 gene in compare to GG and AG genotype. It infers that patients with AA genotype on rs7944135 could have higher expression of MPEG1 and lead to higher immune response against HBV, and results in seroclearance of the HBsAg.

Additional genes, such as HLA, cytokine TNF-\( \alpha \), chemokine receptor 5,\textsuperscript{18} and MCP1,\textsuperscript{21} were found to be associated with the incidence of HBsAg seroclearance through cell-mediated immune responses. Some evidence has been provided that polymorphisms in HLA subtypes are significantly associated with the occurrence of HBsAg seroclearance, such as a polymorphism of HLA-DP rs3077 with haplotype GAT having a 2.17-fold association in a Chinese population.\textsuperscript{40} HLA-DPA1 rs3077 and HLA-DPB1 rs9277355 with A alleles in a Japanese population.\textsuperscript{40} and HLA-B*4001 in Taiwanese population.\textsuperscript{41} There are many polymorphisms of the TNF-\( \alpha \) promoter region that were reported to alter TNF-\( \alpha \)-associated HBV clearance in many populations.\textsuperscript{42} MCP1 with -2518G>A was associated with HBV clearance in a Korean population.\textsuperscript{43}

In this study, we investigated the association of individual SNPs with susceptibility to HBsAg seroclearance in Taiwanese CHB patients. We acknowledge that our study needs to be validated by future studies in other population using more samples, this study offers the findings that polymorphism of MPEG1 have a pivotal association with HBsAg seroclearance in Taiwanese CHB patients.

5. Conclusion

Our present study is a replication of study for a SNP of MPEG1 rs7944135, with susceptibility to HBsAg seroclearance. Our study showed that an HBsAg seroclearance-associated SNP, rs7944135 with AA genotype, solely has a significant association with the loss of the HBsAg in CHB infection in Taiwanese HBV patients.

Acknowledgments

The authors thank the Genomic Research Center, Academia Sinica, Taiwan for providing us the DNA of HBV samples and thanks Ms Mei-Hung Pan for her assistance in coordinating samples.

Author contributions

Conceptualization: Lalu Muhammad Irham, Henry Sung-Ching Wong, Wei-Chiao Chang.

Data curation: Lalu Muhammad Irham, Hwai-I Yang.

Formal analysis: Lalu Muhammad Irham.

Investigation: Lalu Muhammad Irham.

Methodology: Lalu Muhammad Irham, Henry Sung-Ching Wong, Wei-Chiao Chang.

Supervision: Dyah Aryani Perwitasari, Hwai-I Yang, Wei-Chiao Chang.

Validation: Wei-Chiao Chang.

Writing – original draft: Lalu Muhammad Irham.

Writing – review and editing: Lalu Muhammad, Irham Henry Sung-Ching Wong, Dyah Aryani Perwitasari, Wan-Hsuan Chou, Hwai-I Yang, Wei-Chiao Chang.

Lalu Muhammad Irham orcid: 0000-0002-0091-4887.

References

\[1\] Lavanchy D. Hepatitis B virus epidemiology, disease burden, treatment, and current and emerging prevention and control measures. Jo Viral Hepatitis 2004;11:97–107.

\[2\] Seto WK, Lo YR, Pawlotsky JM, et al. Chronic hepatitis B virus infection. Lancet (London, England) 2018;392:2313–24.

\[3\] Burns GS, Thompson AJ. Viral hepatitis B: clinical and epidemiological characteristics. Cold Spring Harb Perspect Med 2014;4:a024935.

\[4\] Qu LS, Liu JX, Zhang HF, et al. Effect of serum hepatitis B surface antigen levels on predicting the clinical outcomes of chronic hepatitis B infection: a meta-analysis. Hepatol Res 2015;45:1004–13.

\[5\] Yang SC, Lu SN, Lee CM, et al. Combining the HBsAg decline and HBV DNA levels predicts clinical outcomes in patients with spontaneous HBeAg serocconversion. Hepatol Int 2013;7:748–99.

\[6\] Coffito CS, Zhou K, Teraza NA, New and old biomarkers for diagnosis and management of chronic hepatitis B virus infection. Gastroenterology 2019;156:355–68.e3.

\[7\] Tai DI, Lin SM, Sheen IS, et al. Long-term outcome of hepatitis B e antigen-negative hepatitis B surface antigen carriers in relation to changes of alanine aminotransferase levels over time. Hepatology (Baltimore, Md) 2009;49:1859–67.

\[8\] Kim JH, Lee YS, Lee HJ, et al. HBsAg seroclearance in chronic hepatitis B: implications for hepatocellular carcinoma. J Clin Gastroenterol 2011;45:64–8.

\[9\] Habeserzetti F, Moenne-Loccoz R, Meyer N, et al. Loss of hepatitis B surface antigen in a real-life clinical cohort of patients with chronic hepatitis B virus infection. Liver Int 2015;35:130–9.

\[10\] Riveiro-Barcuela M, Tabernero D, Calleja JL, et al. Effectiveness and safety of entecavir or tenofovir in a Spanish cohort of chronic hepatitis B patients: validation of the page-B score to predict hepatocellular carcinoma. Dig Dis Sci 2017;62:784–93.

\[11\] Simonetti J, Bulkow L, McMahon BJ, et al. Clearance of hepatitis B surface antigen and risk of hepatocellular carcinoma in a cohort chronically infected with hepatitis B virus. Hepatology (Baltimore, Md) 2010;51:1531–7.

\[12\] Ferreire SC, Chacha SG, Souza FF, et al. Factors associated with spontaneous HBsAg clearance in chronic hepatitis B patients followed at a university hospital. Ann Hepatol 2014;13:562–70.

\[13\] Chu CM, Liaw YF. HBsAg seroclearance in asymptomatic carriers of high endemic areas: appreciably high rates during a long-term follow-up. Hepatology (Baltimore, Md) 2007;45:1187–92.

\[14\] Nam SW, Jung JJ, Baek SH, et al. Clinical outcomes of delayed clearance of serum HBsAg in patients with chronic HBV infection. Korean J Intern Med 2007;22:73–6.

\[15\] Kato Y, Nakao K, Hamasaki K, et al. Spontaneous loss of hepatitis B surface antigen in chronic carriers, based on a long-term follow-up study in Goto Islands, Japan. J Gastroenterol 2000;35:201–5.

\[16\] Ji X, Zhang Q, Li B, et al. Impacts of human leukocyte antigen DQ genetic polymorphisms and their interactions with hepatitis B virus mutations on the risks of viral persistence, liver cirrhosis, and hepatocellular carcinoma. Infect Genet Evol 2014;28:201–9.

\[17\] Hosaka T, Suzuki F, Kobayashi M, et al. HLA-DP genes polymorphisms associate with hepatitis B surface antigen kinetics and seroclearance during nucleos(t)ide analogue therapy. Liver Int 2015;35:1290–302.

\[18\] Seto WK, Wong DK, Kopaniszen M, et al. HLA-DP and IL28B polymorphisms: influence of host genome on hepatitis B surface antigen seroclearance in chronic hepatitis B patients. PloS One 2013;8:e53008.

\[19\] Cheng HR, Liu CJ, Tseng TC, et al. Host genetic factors affecting spontaneous HBsAg seroclearance in chronic hepatitis B patients. PloS One 2013;8:e53008.

\[20\] Kim YJ, Lee HS, Yoon JH, et al. Association of TNF-alpha promoter polymorphisms with the clearance of hepatitis B virus infection. Hum Mol Genet 2003;12:2541–6.
[21] Park BL, Kim YJ, Cheong HS, et al. Association of common promoter polymorphisms of MCP1 with hepatitis B virus clearance. Exp Mol Med 2006;38:694–702.

[22] Chang SW, Fann CS, Su WH, et al. A genome-wide association study on chronic HBV infection and its clinical progression in male Han-Taiwanese. PloS One 2014;9:e97724.

[23] Yeo YH, Ho HJ, Yang HI, et al. Factors associated with rates of HBsAg seroclearance in adults with chronic HBV infection: a systematic review and meta-analysis. Gastroenterology 2019;156:635–46.e9.

[24] O’Brien TR, Yang HI, Groover S, et al. Genetic factors that affect spontaneous clearance of hepatitis C or B virus, response to treatment, and disease progression. Gastroenterology 2019;156:400–17.

[25] Yuen MF, Wong DK, Sablon E, et al. HBsAg seroclearance in chronic hepatitis B in the Chinese: virological, histological, and clinical aspects. Hepatology (Baltimore, Md ) 2004;39:1694–701.

[26] Chu CM, Law YF. Hepatitis B surface antigen seroclearance during chronic HBV infection. Antivir Ther 2010;15:133–43.

[27] Kim TH, Lee EJ, Choi JH, et al. Identification of novel susceptibility loci associated with hepatitis B surface antigen seroclearance in chronic hepatitis B. PloS One 2018;13:e0199094.

[28] Park YM, Lee SG. Clinical features of HBsAg seroclearance in hepatitis B virus carriers in South Korea: a retrospective longitudinal study. World J Gastroenterol 2016;22:9836–43.

[29] Wang SH, Chen PJ, Yeh SH. Gender disparity in chronic hepatitis B: mechanisms of sex hormones. J Gastroenterol Hepatol 2015;30:1237–45.

[30] Ahn SH, Park YN, Park JY, et al. Long-term clinical and histological outcomes in patients with spontaneous hepatitis B surface antigen seroclearance. J Hepatol 2005;42:188–94.

[31] Arase Y, Ikeda K, Suzuki F, et al. Long-term outcome after hepatitis B surface antigen seroclearance in patients with chronic hepatitis B. Am J Med 2006;119:71.e9–16.